Skip to main content

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs. In December 2025, zurletrectinib received approval for the treatment of adult and adolescent patients (aged 12 years...

Continue reading

PONY AI Inc. Achieved Gen-7 Robotaxi UE Breakeven in Shenzhen, Strengthening Path to Scalable Commercialization

SHENZHEN, China, March 02, 2026 (GLOBE NEWSWIRE) — Pony AI Inc. (“Pony.ai” or the “Company”) (NASDAQ: PONY; HKEX: 2026), a global leader in achieving large-scale mass production and commercialization of autonomous driving technology, today announced that it has achieved seventh-generation (“Gen-7”) Robotaxi unit economics (“UE”) breakeven1 in Shenzhen. This milestone underscores Pony.ai’s capability to realize a sustainable business model, laying a solid foundation to accelerate scale-up over a multi-year horizon. Driven by surging user demand and optimized operational efficiency, Pony.ai’s commercial operations in Shenzhen have delivered outstanding results. As of February 28, the one-month daily average net revenue per Gen-7 Robotaxi has reached RMB338, with a daily average of 23 orders per vehicle. These figures demonstrate...

Continue reading

Veea Platform Solution to Address Cybersecurity Challenges Nationwide for Businesses in Mexico

At Mobile World Congress 2026 in Barcelona, March 2-4, Veea will demonstrate a first-of-a-kind Plug-and-Play 5G FWA with AI-Enhanced Cybersecurity and Value-added Services BARCELONA, Spain, March 01, 2026 (GLOBE NEWSWIRE) — Veea Inc. (“Veea”), a leading-edge supplier of managed networking and secure multiaccess edge computing platform products and solutions, today announced the planned launch of Veea SecureConnect™ service by Telcel in Mexico this week. Veea SecureConnect, being demonstrated at Mobile World Congress, is expected to be offered over a 5G network with one of the broadest coverages in Mexico. Veea SecureConnect is targeted to businesses and enterprises such as pharmacies, branch offices, clinics, medical and dental offices, retailers, QSRs, restaurants, gyms, warehouses, travel agencies, SOHO users, professional...

Continue reading

CORRECTION — WeShop Helps Pet Lovers Turn Everyday Pet Spending into Ownership

NEW YORK, March 01, 2026 (GLOBE NEWSWIRE) — In a release issued Wednesday, February 25, 2026 by WeShop Holdings Limited (NASDAQ: WSHP), please note direct references to retailer names should not appear. The corrected release follows: WeShop Holdings Limited (“WeShop” or the “Company”) (NASDAQ: WSHP), the world’s first community-owned social commerce platform, allows shoppers to earn equity while they shop at leading pet retailers giving the over 94 million pet owners in the U.S. even more ways to save while caring for their animals. Within the WeShop app, members can shop a curated selection of pet essentials, including premium pet food, treats, toys, grooming products, health and wellness items, and everyday supplies. By featuring trusted category leaders in its marketplace, WeShop connects routine pet care spending to its ownership-driven...

Continue reading

Closing date for director nominations

TORONTO and PERTH, Western Australia, March 01, 2026 (GLOBE NEWSWIRE) — Cygnus Metals Limited (ASX:CY5) advises, in accordance with ASX Listing Rule 3.13.1, that the Annual General Meeting of the Company (“Meeting”) will be held in West Perth, Western Australia on Friday, 1 May 2026. Further details in respect of the Meeting will be provided in the Notice of Meeting to be dispatched to shareholders prior to the Meeting. An item of business at the Meeting will be the election and re-election of certain directors. In accordance with rule 6.1(p)(i) of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Monday, 9 March 2026. Any nominations must be received at the Company’s registered office no later than 5.00pm (Perth time) on Monday,...

Continue reading

Investor Education Webinar

The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate cancer. Speakers:Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Centre (MTIC); Paul Yonover, MD, FACS, Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance; Chief of Urology at Ascension Saint Joseph Hospital, Chicago; and Darren Patti, PharmD, Telix Group Chief Operating Officer.The webinar will...

Continue reading

Avavav Turns the Runway Inside Out – and Oatly Pours it Forward

Where fashion performance meets oat drink innovationMILAN, March 01, 2026 (GLOBE NEWSWIRE) — Avavav and Oatly, the world’s original and largest oat drink company, come together at Milan Fashion Week for Avavav’s Autumn/Winter 2026 show, to blur the boundaries between fashion, performance and flavor. Staged as a reversed runway, the show turned the traditional format inside out: guests become the ones being observed, while models take their place as spectators. Continuing Avavav’s ongoing exploration of fashion as performance rather than presentation, the concept plays with exposure, perspective and power, reframing who gets seen, and who does the seeing. Within this immersive world, Oatly didn’t just show up; it made the performance drinkable, translating silhouettes into sips. A shared language of culture and experimentation Speaking...

Continue reading

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

— –18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity — — March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity — BOSTON, March 01, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity (HO). This new data set includes 12 patients from a Japanese cohort and 10 supplemental patients who were enrolled in addition to the primary 120-patient...

Continue reading

Apple iSports Group Appoints Ian Wilding as Fractional Chief Innovation Officer to Support Strategic Growth and Nasdaq Readiness

IRVINE, Calif., March 01, 2026 (GLOBE NEWSWIRE) — Apple iSports (OTC-QB: AAPI) (“Company” or “Apple iSports” or “AiS”), a digital gaming, entertainment, and technology company, announced the appointment of Ian Wilding, Founder and CEO of Hangar 75, as Fractional Chief Innovation Officer. In this role, Wilding will work closely with the Apple iSports executive team and board to guide strategic innovation initiatives, strengthen decision-making discipline, and support the Company’s progression from an OTC-QB-listed business toward Nasdaq uplisting. Apple iSports operates at the intersection of gaming infrastructure, digital entertainment, and emerging market opportunities. As the Company continues to scale and prepare for the increased scrutiny associated with a potential Nasdaq listing, the role will focus on ensuring that innovation...

Continue reading

Apple iSports Signs Joint Venture Agreement with Apple iCasino

IRVINE, Calif., March 01, 2026 (GLOBE NEWSWIRE) — Apple iSports (OTC-QB: AAPI) (“Company” or “Apple iSports” or “AiS”), a gaming, entertainment, and technology services company, is pleased to announce it has signed a Joint Venture Agreement (“Agreement “or “JV Agreement”) with AiC Enterprises LLC, Belize (“AiC“), a premier, online gaming company. Key HighlightsAiS and AiC have entered into a JV Agreement to supply a gaming products platform and technical services to business enterprises and consumer clients. Additionally, AiS has licensed the “apple-i” brand to AiC, which both companies will jointly promote in the gaming ecosystem. The Board of Directors of both AiC Enterprises and Apple iSports approved the Agreement, which was executed with legal effect on February 28, 2026 (Asia-Pacific time). AiC will utilize...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.